Skip to main content

Fiscal Wizard · Single-issue tearsheet

JSPR / Jun 22, 2026 Run #7598

JSPR

Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.

Composite verdict

F 9.6 / 100
Bearish setup · Trend Following 16 drivers · 5 gates blocking
  • 52-Week Proximity
  • Trendline Break
  • ADX DI Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 445th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 1Mean-reversion Neutral 50
  • Late-stage trendTrend signals have been live for 238 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

19.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 77
Return on Capital Employed 0
P/B 75
Greenblatt ROC 0
Free Cash Flow Yield 0

Technicals Bearish

0.0 / 100

Bearish setup leads (52-Week Proximity, Trendline Break, ADX DI Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
52-Week Proximity 9
Trendline Break 10
Rate of Change 16

Risk Gates

5 blocking 3 caution

5 guards active, 19 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for JSPR.